Gujarat Themis Biosyn Reports Significant Financial Improvements and Market Outperformance

Gujarat Themis Biosyn, a small-cap player in the Pharmaceuticals and Biotechnology sector, has recently undergone a financial trend adjustment, reflecting a notable improvement in its performance metrics for the quarter ending September 2025. The company reported its highest net sales at Rs 42.35 crore, alongside a peak PBDIT of Rs 20.95 crore. The operating profit margin also reached an impressive 49.47%, indicating strong operational efficiency.
Key financial indicators such as profit before tax (PBT) less other income stood at Rs 17.94 crore, while the profit after tax (PAT) was recorded at Rs 14.26 crore. The earnings per share (EPS) also hit a high of Rs 1.31, showcasing the company's robust profitability.

In terms of market performance, Gujarat Themis Biosyn has outperformed the Sensex over various time frames. Year-to-date, the stock has returned 48.72%, significantly higher than the Sensex's 6.91%. Over the past three years, the company has achieved a remarkable return of 334.26%, compared to the Sensex's 37.82%. This performance underscores the company's strong market position and operational success in a competitive industry landscape.